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  The tumour suppressor BRCA1 is mutated in familial breast and ovarian cancer but its role 
in protecting other tissues from DNA damage has not been explored. Here we show a new 
role for BRCA1 as a gatekeeper of cardiac function and survival. In mice, loss of   BRCA1   in 
cardiomyocytes results in adverse cardiac remodelling, poor ventricular function and higher 
mortality in response to ischaemic or genotoxic stress. Mechanistically, loss of cardiomyocyte 
BRCA1 results in impaired DNA double-strand break repair and activated p53-mediated pro-
apoptotic signalling culminating in increased cardiomyocyte apoptosis, whereas deletion of the 
p53 gene rescues   BRCA1 -deﬁ  cient mice from cardiac failure. In human adult and fetal cardiac 
tissues, ischaemia induces double-strand breaks and upregulates BRCA1 expression. These data 
reveal BRCA1 as a novel and essential adaptive response molecule shielding cardiomyocytes 
from DNA damage, apoptosis and heart dysfunction.   BRCA1   mutation carriers, in addition to 
risk of breast and ovarian cancer, may be at a previously unrecognized risk of cardiac failure.                
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 G
ermline mutations in the tumour suppressor gene   BRCA1  
are highly penetrant for the increased risk of breast and ovar-
ian cancer syndromes  1,2 .   BRCA1   is mutated in up to 50  %   of 
inherited breast cancers and individuals who carry a defective copy 
of the gene have a 50  –  85  %   cumulative lifetime risk of developing 
breast cancer and a 12  –  60  %   chance of developing ovarian cancer  3 . 
BRCA1 functions as a   ‘  caretaker  ’   of genome stability and exerts mul-
tiple eff  ects on key cellular processes involved in DNA damage repair, 
transcriptional regulation, ubiquitination and cell-cycle control  4,5 . 
 Th  e    BRCA1  gene is composed of 24 exons and full-length  BRCA1  
encodes a   ~  220-kD protein  6,7  . Exon 11 of the   BRCA1   gene is the 
largest exon spanning   ~  60  %   of the entire   BRCA1   gene 3 .  Th  e  exon 
11 encoded domain of BRCA1 interacts and also colocalizes with 
RAD51 at the sites of DNA double-strand breaks (DSBs) to activate 
RAD51-mediated homologous recombination repair of DSBs  3,8 . 
Notably, BRCA1-defi  cient cells exhibit a defi  cit in RAD51-mediated 
homologous recombination repair of DSBs and hypersensitivity to 
DNA-damaging agents  9 . 
  Un-repaired DNA damage is a trigger for apoptosis, which is 
important not only in the development of cancer syndromes but also 
represents a common pathophysiological basis for diverse chronic 
diseases including cardiovascular disease  10 – 13  . Indeed, ischaemia-
induced DSBs  14   and apoptosis have been proposed as a key mecha-
nism of cell death that occurs during cardiac ischaemia  15 – 17 .  Apop-
tosis is also thought to contribute to the progressive loss of cardiac 
function with eventual transition towards overt cardiac failure, a 
leading cause of cardiac morbidity and death worldwide  15 – 17 . 
  As BRCA1 has an integral role in promoting DNA damage 
repair, we hypothesized that BRCA1 regulates cardiomyocyte sur-
vival and that loss of function would provoke increased ischaemia-
induced DNA damage, apoptosis and subsequent overt cardiac 
failure. We report herein for the fi  rst time that the loss of BRCA1 
in cardiomyocytes leads to increased susceptibility to myocardial 
infarction (MI) and genotoxic drug (doxorubicin)-induced apop-
tosis and cardiac dysfunction. We also report that ischaemia leads 
to signifi  cantly higher DSBs and upregulation of BRCA1 expres-
sion, arguably to promote DSB repair in human adult and fetal 
ischaemic heart tissues. From a translational standpoint, these 
observations highlight a previously unrecognized role of BRCA1 
as a gatekeeper of cardiac structure and function, and suggest that 
individuals carrying   BRCA1   mutations may be at a previously 
unrecognized risk of cardiac failure, particularly in the setting of 
ischaemic or genotoxic stressors.   
 Results  
  Cardiomyocyte-specifi  c   BRCA1   knockout mice   .    To  delineate  the 
role of BRCA1 in the heart, we fi  rst measured the basal transcript 
levels of BRCA1 in the diff  erent organs of wild-type (WT) mice and 
observed low expression of the BRCA1 transcript in murine hearts 
(  Fig. 1a  ). In contrast, WT mice that had undergone a MI exhibited 
marked upregulation of BRCA1 in their remote myocardia, an eff  ect 
that was signifi  cant within 36     h and that remained for a week post-
MI (  Fig. 1b  ). Next, to directly elucidate the involvement of BRCA1 
in cardiac structure, function and survival, and to circumvent the 
embryonic lethality associated with systemic loss of  BRCA1  (ref.  18 ), 
we applied the   Cre-loxP   system to specifi   cally disrupt   BRCA1  
expression in cardiomyocytes. Conditional inactivation of   BRCA1  
in cardiomyocytes was achieved by crossing mice homozygous 
for the exon 11 fl  oxed   BRCA1   allele   (BRCA1    fl    / fl     )   with  hemizygous 
mice expressing   Cre-recombinase   under the control of the   α  -myosin 
heavy chain (  α  MHC-Cre    tg /    )   promoter as demonstrated in 
 Fig.  1c  19,20  . Mice of the   α  MHC-Cre    tg /    ;BRCA1    fl    / fl      background are 
denoted as cardiomyocyte-specifi  c   BRCA1   homozygous  knockouts 
(CM-BRCA1      −      /      −       ). Mice, regardless of their genotypes, were viable, 
fertile and were born in the expected Mendelian ratios. Analysis 
of genomic DNA from the heart, brain, liver and skeletal muscles 
revealed that the   Cre-  mediated recombined allele was only present 
in heart samples but not in the brain, liver and muscles of CM-
BRCA1      +      /      −        and CM-BRCA1      −      /      −        mice  ( Fig.  1d ).  Successful  deletion 
of BRCA1 at the protein level was confi  rmed by western blot analysis 
using an antibody that recognizes the exon 11 encoded C terminus 
of BRCA1. Graded cardiac BRCA1 protein levels were noted with 
the highest observed in samples from WT control mice, moderate 
in CM-BRCA1      +      /      −        mice and the lowest in CM-BRCA1      −      /      −        mice 
( Fig. 1e , full blots are shown in  Supplementary Figure S2 ). Although 
BRCA1 immunostaining of left   ventricular (LV) sections further 
confi  rmed reduced BRCA1 expression in the cardiomyocytes of 
CM-BRCA1      +      /      −        and CM-BRCA1      −      /      −        mice, BRCA1 expression in 
most of the non-cardiomyocytes was found to be similar across 
the study groups (  Fig. 1f  ). Taken together, these fi  ndings validate 
the successful generation of mice with cardiomyocyte-specifi  c 
inactivation of full-length BRCA1.     
  Cardiomyocyte  BRCA1  loss and the unstressed heart   .    Th  e  baseline 
(10 – 12 weeks old) cardiac structure and function of CM-BRCA1      −      /      −       
mice and their WT control littermates were indistinguishable 
( Table  1 ).  Th  e WT control group included littermates with the 
  BRCA1        +      /      +       ,   BRCA1    fl    /      +       ,   BRCA1    fl    / fl      and   α  MHC-Cre    tg /    ;BRCA1        +      /      +        
genotypes. Although high levels of   Cre-recombinase   in the heart 
have been associated with cardiomyopathy in aged mice, this 
pathology is evident only in mice that express   Cre-recombinase   50 
to 100 times greater than that in TG9, a   α  MHC-Cre -transgenic 
strain that does not develop congestive heart failure  21 .  Nonetheless, 
to exclude the possible involvement of   Cre -mediated  cardiomyop-
athy in our model, parallel studies were conducted on littermates 
expressing the   Cre- only  ( α  MHC-Cre    tg /    ;BRCA1        +      /      +       )  background. 
As our results indicated no diff  erences between the   Cre- only  mice 
and the other WT control littermates at baseline and aft  er MI, the 
former animals were included in the WT control group. Molecular 
work on apoptosis, as evaluated by TdT-mediated dUTP nick end 
labeling (TUNEL) staining of LV sections, indicated similar pat-
terns between the groups (  Fig. 1g  ). Th  e extent of DSBs, as meas-
ured by   γ  H2A.X foci formation (  Fig. 1h  ), also did not reveal any 
baseline diff  erences between hearts from CM-BRCA1      −      /      −        mice and 
their WT control littermates. Hence, in the absence of stress, cardio-
myocyte-specifi  c deletion of   BRCA1   resulted in no grossly apparent 
cardiac phenotype.     
  Cardiomyocyte   BRCA1   loss and post-MI mortality   .    To  explore 
the function of BRCA1 in the heart, we monitored the survival of 
CM-BRCA1      −      /      −        mice, CM-BRCA1      +      /      −        mice and their WT control 
littermates for 22 weeks following MI. Post-MI mortality in CM-
BRCA1      −      /      −        mice was profoundly higher relative to that for their 
WT control littermates and CM-BRCA1      +      /      −        mice demonstrated 
intermediate but signifi  cantly higher post-MI mortality compared 
with the WT controls (  Fig. 2a  ). Tachypnea, hunched back posture 
and raised fur were the most evident visual symptoms before death 
in CM-BRCA1      −      /      −        mice in comparison with the WT control lit-
termates. At post-MI autopsies, pleural eff  usion and pulmonary 
oedema were consistently observed in CM-BRCA1      −      /      −        mice but 
not in the control mice. To determine if the elevated post-MI mor-
tality observed with CM-BRCA1      −      /      −        mice is associated with larger 
infarct sizes, myocardial infarcts 4 weeks post-MI were measured 
and indeed, as shown in   Fig. 2b  , CM-BRCA1      −      /      −        mice exhibited 
a larger mean infarct size relative to their WT control littermates. 
Th   ere were no diff  erences in the areas at risk between the groups 
24     h post-MI (  Fig. 2c  ). Furthermore, a   ~  1.5-fold increase in the LV 
radius to LV wall thickness (r  /  h) ratio was observed in CM-
BRCA1      −      /      −        mice relative to the WT control littermates (  Fig. 2d  ). 
Collectively, these fi  ndings demonstrate that loss of BRCA1 in cardio-
myocytes is associated with poor cardiac outcomes, adverse cardiac 
remodelling and increased mortality in response to ischaemic stress.     ARTICLE   
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  Cardiomyocyte   BRCA1   loss and post-MI cardiac changes   .  
    Echocardiographic assessment of cardiac structure and func-
tion post-MI revealed reduced ejection fraction and fractional 
shortening (  Fig. 3a  ) as well as increased ventricular dimensions 
in CM-BRCA1      −      /      −        mice compared with their WT control lit-
termates (  Fig. 3b  ). Congruent with these observations, invasive 
pressure  –  volume measurements also indicated twofold greater 
end-systolic and end-diastolic volumes and 50  %   lower ejection 
fractions in CM-BRCA1      −      /      −        mice  post-MI  ( Table  2 ;   Fig.  3c ). 
Th  e reduced fi  rst derivative of pressure during isovolumic con-
traction (  dP / dt   max) and relaxation (  dP / dt   min) along with the 
rightward shift   of the volume intercept (  Fig. 3d,e  ) suggest that the 
impairment in cardiac function in CM-BRCA1      −      /      −        mice arose to 
a large degree because of the exaggerated LV dilation post-MI. 
CM-BRCA1      −      /      −        mice displayed a decrease in heart weight  /  body 
weight ratio (5.3       ±    0.9  and  4.1    ±    0.3;  WT  versus  CM-BRCA1     −      /      −      , 
  P     <    0.01;  Student ’ s   t  -test) in response to MI, when compared with 
their WT control littermates. We also analysed the transcript lev-
els of brain natriuretic peptide, which is an established marker 
for the heart failure and demonstrate a signifi  cant upregulation in 
the hearts of CM-BRCA1      −      /      −        in comparison to the WT control 
littermates post-MI (  Fig. 3f  ). 
 To  confi  rm the robustness of our observations, we evaluated 
the cardiac phenotype of CM-BRCA1      −      /      −        mice that had been 
subjected to an alternative stressor, the chemotherapeutic agent 
doxorubicin  (single  dose,  10   mg   kg     −     1 ,  intraperitoneally).  We 
report that CM-BRCA1      −      /      −        mice treated with doxorubicin exhibit 
worse cardiac function and more cardiomyocyte apoptosis com-
pared with control mice 7-days post-treatment (  Fig. 3g,h  ). Taken 
together, these data indicate that defi  ciency of full-length BRCA1 in 
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ventricle;   n     =    3 – 4.  ( b  ) Cardiac   BRCA1   transcript levels in WT mice post-MI;   n     =    4,   *  P     <    0.01  versus  sham-operated  mice  (pair-wise  ﬁ  xed reallocation 
randomization test). (  c  ) Scheme of   Cre  -mediated deletion of exon 11 of the   BRCA1   gene. Black arrows denote binding sites of primers used for genotyping. 
(  d  ) Genotypic identiﬁ  cation of cardiomyocyte-speciﬁ  c   BRCA1   knockout mice. Genomic ampliﬁ  cation of the 531     bp product of primer pair 004  /  005 
indicates the presence of exon 11. Presence of the 621     bp product of primer pair 004  /  006 indicates the absence of the binding site for primer 005. CM-
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 *  P         <       0.01 versus control group (analysis of variance with post-hoc Bonferroni  ’  s correction). (  f  ) Representative micrographs for baseline cardiac BRCA1 
levels. Brown areas denote BRCA1 expression with haematoxylin counterstaining appearing blue. Scale bar, 20       μ m.  ( g  ) Extent of apoptosis (TUNEL) in LV 
sections.   n     =    3 – 4,  scale  bar,  50    μ m.  ( h  ) DNA DSBs (  γ  H2A.X foci formation) in LV sections. Liver and LV sections from doxorubicin-treated (10     mg     kg      −     1 , 
intraperitoneally 7 days before euthanasia) control mice were used for positive control assessments of   γ  H2A.X and TUNEL staining, respectively. 
  n     =    3 – 4,  scale  bar,  10    μ  m. Error bars in   a   and   b,   and   e   represent s.e.m. and s.d,. respectively.   ARTICLE
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cardiomyocytes results in increased susceptibility to cardiac failure 
under both ischaemic and genotoxic conditions.     
  Cardiomyocyte   BRCA1   loss and cardiomyocyte death post-MI   .  
    Programmed cardiomyocyte death has been suggested to under-
lie progressive ventricular remodelling and ischaemic cardiac fail-
ure  16,22  . As BRCA1 exerts a multitude of eff  ects to promote DNA 
repair and limit apoptotic cell death pathways, we postulated that 
cardiomyocyte specifi  c loss of BRCA1 may provoke cardiac failure 
through a similar mechanism. We demonstrate that the prevalence 
of apoptotic cardiomyocyte nuclei, as identifi  ed by TUNEL staining, 
was higher in LV sections from CM-BRCA1     +      /      −       and CM-BRCA1     −      /      −       
mice compared with those from their WT control littermates post-
MI (  Fig. 4a  ). To discriminate apoptosis in cardiomyocytes from 
non-myocytes, myocardial sections were doubly stained for TUNEL 
and the cardiomyocyte-specifi  c structural protein   α -myosin  heavy 
chain. Th   is data was further confi  rmed by immunostaining for cas-
pase-3 and western blot for cleaved caspase-3, which was increased 
post-MI in the LV sections of CM-BRCA1      −      /      −        in comparison with 
WT control littermates (  Fig. 4b,c  ). 
  BRCA1-null mutants die embryonically due to p53 hyperac-
tivity but this embryonic lethality can be partially rescued by p53 
defi  ciency  18  . Upregulation of p53 due to hypoxia or forced expres-
sion of p53 is suffi   cient to induce apoptosis in cardiomyocytes  23 , 
and importantly, p53-null mice subjected to MI exhibit reduced 
apoptosis and improved survival  24  . In line with these fi  ndings, we 
also demonstrate an increase in total p53 expression in the hearts 
of CM-BRCA1      −      /      −        compared with their WT control littermates 
post-MI (  Fig. 4b  ). Th  e p53-dependent apoptotic signalling path-
way involves the Bcl-2 family of proteins (Bcl-2 and Bax), which 
are recognized as major regulators of cardiomyocyte apoptosis and 
have been implicated as a critical mediator of cardiomyocyte sur-
vival decisions during heart failure  16,25,26  . Indeed, the increase in 
cardiomyocyte apoptosis in CM-BRCA1      −      /      −        mice was associated 
with a loss of myocardial pro-survival Bcl-2 with a concomitant 
increase in pro-apoptotic Bax leading to a   ~  12.5 fold increase in 
the Bax to Bcl-2 ratio (  Fig. 4b,d  ), hence shift  ing the balance from 
a survival to apoptotic milieu. Th  is shift   was further associated 
with elevated levels of total and cleaved caspase-3 compared with 
the corresponding control group (  Fig. 4b  , full blots are shown in 
 Supplementary  Figure  S3 ).   
  Cardiomyocyte   BRCA1   loss and DSB repair post-MI   .    Given  the 
central role of BRCA1 in DNA DSB repair, we postulated that an 
ischaemic insult in the setting of BRCA1 defi  ciency may result in an 
increased burden of DSBs, setting the stage for progressive cardiomy-
ocyte apoptosis  4,5,27 . One of the fi  rst steps in the cellular response to 
DSBs is phosphorylation of histone H2A.X at Ser139, referred to as 
  γ H2A.X 4,28 . At these sites of DNA damage,  γ H2A.X appears to have a 
critical function in the recruitment of additional DNA repair factors 
and represents an early and sensitive marker of chromatin modi-
fi  cation before cells undergo the process of repair or apoptosis  28 . 
Indeed, a   ~  2.5-fold higher expression of   γ H2A.X  was  observed 
in cardiomyocyte nuclei from the hearts of CM-BRCA1      −      /      −        mice 
compared with corresponding sections from control animals 48      h 
post-MI (  Fig. 4e  , full blots are shown in   Supplementary Figure S3  ). 
Although aft  er 72      h, this DNA damage signal resolved in control 
mice, and a persistent   γ  H2A.X signal was observed in LV sections 
of CM-BRCA1      −      /      −        mice (  Fig. 4e,f  ). Moreover, BRCA1 is required 
for RAD51-foci formation at the sites of DNA damage, which then 
activates RAD51-mediated repair of DSBs  29 .  Th   erefore, it became 
of interest to evaluate RAD51-foci formation in myocardial sam-
ples from control and CM-BRCA1      −      /      −       mice. Although control mice 
exhibited evidence for post-MI RAD51-foci formation, such foci 
were signifi  cantly reduced in number in mice with cardiomyocyte-
specifi  c loss of BRCA1 (  Fig. 4g  ). 
  Increased doxorubicin-induced cardiac dysfunction and apop-
tosis observed in CM-BRCA1      −      /      −        mice correlated with increased 
levels of DSBs in the left   ventricle in comparison with the WT 
control littermates (  Fig. 4h  ). Degree of DSBs repair was measured 
by the extent of RAD51-foci formation, which demonstrated sig-
nifi  cantly reduced RAD51-foci in the left   ventricle of doxorubicin-
treated CM-BRCA1      −      /      −        mice (  Fig. 4i  ). Collectively, these data 
suggest that a reduction in cardiomyocyte BRCA1 activity leads to 
unresolved DNA damage and the absence of eff  ective homologous 
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     Figure  2     |          Loss  of  cardiomyocyte-speciﬁ  c BRCA1 leads to increased 
mortality following myocardial infarction. (  a )  Post-MI  Kaplan – Meier 
survival curves for WT control (green;   n     =    30),  CM-BRCA1     +      /      −        (magenta; 
  n     =    18)  and  CM-BRCA1     −      /      −        (blue;   n     =    26)  littermates.   *  P     <    0.01  (Log-rank 
and Gehan  –  Wilcoxon tests). (  b  ) Representative baseline and post-MI 
(4 weeks) myocardial sections (scale bar, 1     mm). Macroscopic 
measurements of infarct sizes.   n     =    9 – 11.  ( c )  Quantiﬁ  cation of post-MI 
(24     h) myocardial areas at risk;   n     =    3 – 4.  ( d  ) Post-MI LV radius-to-septum 
thickness ratio (r  /  h);   n     =    10.  Error  bars  in   b  –  d   represent s.d. with   *    P     <     0 . 0 5  
versus control values in all cases (Student  ’  s   t -test).  
  Table  1       |     Echocardiographic  assessments  indicate  that  control 
and CM-BRCA1      −      /      −        mice exhibit similar cardiac function at 
baseline. 
    Cardiac  parameters     Control     CM-BRCA1       −      /      −        
   Heart  rate  (bpm)   456    ±    2 7    4 2 3     ±    4 3  
   LV  end  diastolic  dimension  (cm)   0.381    ±    0.038   0.386    ±    0 . 0 3 2  
   LV  end  systolic  dimension  (cm)   0.276    ±    0.042   0.278    ±    0 . 0 3 7  
   LV  ejection  fraction  ( % )   61.0    ±    1 1 .1    6 2 . 0     ±    10.5 
   LV  fractional  shortening  ( % )   27.6    ±    7.3   28.2    ±    7.1  
     Data  are  mean    ±    s.d.,   n =12.   ARTICLE   
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recombination repair sets the stage for increased p53-mediated 
apoptosis and ensuing cardiac failure.     
  Heterozygous p53 loss rescues BRCA1-defi  cient mice from MI   .  
    As previously stated, the phenotype associated with systemic loss 
of BRCA1 is attenuated with concomitant loss of p53 (ref.   18  ). 
Hence it became plausible to explore the eff  ect of BRCA1 loss in 
cardiomyocyte with compound systemic deletion of p53 in the set-
ting of ischaemic stress. To establish the role for p53 activation in 
the impaired cardiac stress response observed in BRCA1-defi  cient 
mice, we crossed   α  MHC-Cre    tg /    ;BRCA1    fl    / fl      mice with   p53        +      /      −        
mutants to generate mice that have one allele of   BRCA1   in their 
cardio  myocytes along with the systemic loss of one allele of   p53 
(  α  MHC-Cre    tg /    ;BRCA1    fl    /      +        ;p53        +      /      −         otherwise denoted as CM-
BRCA1      +      /      −      ;p53     +      /      −       ). We report that CM-BRCA1      +      /      −      ;p53     +      /      −        mice 
are protected against MI-induced apoptosis and cardiac dysfunc-
tion in comparison to CM-BRCA1      +      /      −        mice (  Fig. 5a,b  ). 
  To further support these fi   ndings and also to mimic clini-
cally relevant human BRCA1-deffi   cient conditions, we generated 
mice with a compound systemic deletion of one allele of 
both   BRCA1   and   p53  . Following MI, compound heterozygous 
BRCA1      +      /   Δ 11 ;p53     +      /      −        mice demonstrated that systemic loss of 
one allele of p53 rescued BRCA1      +      /   Δ 11   heterozygous mice against 
MI-induced cardiac dysfunction (ejection fraction: 34.0        ±    4 %   and 
48.9    ±    4.9 %   for  BRCA1     +      /   Δ 11   and  BRCA1     +      /   Δ 11 ;p53     +      /      −      ,  respec-
tively;   P     <    0.01;  Student ’ s   t -test).  Th  us, loss of BRCA1 provokes 
ischaemia-induced cardiomyocyte apoptosis through upregulation 
of p53-mediated cell death pathways, which is causally implicated in 
ischaemic heart failure.     
  Cardiac BRCA1 is upregulated following ischaemia in humans   .  
    To further explore the clinical relevance of BRCA1, we assessed 
BRCA1 expression in human cardiac samples following ischaemic 
stress. First, we utilized a well-validated model of human atrial 
cardiac ischaemia and reperfusion  30   wherein atrial biopsies were 
obtained intraoperatively from patients before and aft  er initiation of 
cardiopulmonary bypass (CPB). We measured BRCA1 expression 
levels and the extent of DSBs by immunoblot and immunostaining. 
BRCA1-mediated DSB repair was evaluated by immunostaining 
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       Figure  3     |          Loss  of  cardiomyocyte-speciﬁ  c BRCA1 leads to aberrant cardiac changes following ischaemic and genotoxic stress. (  a  ) LV performance 
(ejection fraction (LVEF) and fractional shortening (LVFS)) 4 weeks post-MI, as assessed by echocardiography;   n     =    4 – 6.  ( b  ) Representative M-mode 
echocardiograms with LV end systolic and end diastolic diameters annotated in white and yellow, respectively. (  c  ) LV end diastolic volume (LVEDV).   n     =     9  –
 11.  ( d  ) Representative pressure  –  volume loops of infarcted hearts (4 weeks post-MI) from CM-BRCA1      −      /      −        mice and their WT control littermates. (  e )   dP / dt  
values.   n     =    9 – 11.  ( f )   BNP   expression 4 weeks post-MI as determined by real-time PCR on cDNA synthesized from total LV RNA.   GAPDH   was used as an 
endogenous control.   n     =    5 – 6.  ( g  ) Echocardiography results showing LV function. (  h  ) Cardiomyocyte apoptosis (TUNEL staining; arrows) 7 days following 
a single treatment with 10     mg     kg      −     1   (intraperitoneal) doxorubicin. Scale bar, 10       μ m,   n     =    4 – 6.  Error  bars  in  ( a ,   c ,   e  –  h  ) represent s.d. with   *    P     <    0.05  versus 
control values in all cases (Student  ’  s   t -test).  
  Table  2       |     Echocardiographic  post-MI  invasive 
pressure-volume assessments. 
    Parameters     Control     CM-BRCA1       −      /      −        
      LV end systolic volume (  μ l)   5.8    ±    2.4   12.8    ±    6.3* 
      LV end diastolic volume (  μ l)   7.4    ±    2.9   14.1    ±    7. 0 *  
   LV  end  systolic  pressure  (mmHg)   100    ±    1 4    9 2     ±    8  
   LV  end  diastolic  pressure  (mmHg)   23    ±    9   19    ±    9  
   LV  ejection  fraction  ( % )   44.1    ±    15.7   21.3    ±    5.4  †   
   Cardiac  output  ( μ l   min     −     1 )   2206    ±    8 7 2    1 4 7 5     ±    467* 
   Stroke  work  (mmHg    ×     μ l)   307    ±    137   164    ±    65* 
       +      dP / dt   (mmHg   s     −     1 )   6392    ±    1616   4817    ±    67 8 *  
       −      dP / dt   (mmHg   s     −     1 )       −    5528    ±    1 2 6 8        −     4 1 0 1     ±    885* 
      τ     (Glantz,  ms)   16.5    ±    4 .4    2 6 . 2     ±    6.9* 
      n =9 – 11.  Data  are  mean    ±    s.d.  with  * P     <    0.05,    †   P     <    0.01  versus  control  (Student’s   t -test).   ARTICLE
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for RAD51. We report that human atria subjected to perioperative 
ischaemia and reperfusion (post-cardioplegia (CP)  /  CPB) demon-
strated higher BRCA1 expression (  Fig. 6a,b  ). Increased BRCA1 in 
the post-CP  /  CPB atrial biopsies were associated with signifi  cantly 
higher levels of   γ  H2A.X expression and   γ H2A.X-foci  formation 
demonstrating more ischaemia-induced DSBs (  Fig. 6c,d  ). Th  is  phe-
notype was accompanied with higher extent of BRCA1-mediated 
DSB-repair as evident by increased numbers of RAD51-foci com-
pared with those from pre-CPB subjects (  Fig. 6d  ). 
  Second, to extend our observations to a model of chronic ischae-
mic heart disease, we obtained ventricular biopsies from patients 
undergoing open-heart surgery. BRCA1 protein levels in ventricu-
lar biopsies from patients undergoing valvular surgery without 
clinical signs and symptoms of ischaemia (non-ischaemic group) 
were compared with tissues from patients with documented coro-
nary artery disease undergoing coronary artery bypass surgery 
(ischaemic group). We report that human ventricular tissues from 
patients with ischaemic heart disease demonstrated higher levels of 
BRCA1 compared with those from subjects without ischaemic heart 
disease (  Fig. 6e  ). 
 Th   ird, to evaluate whether this ischaemia-induced upregulation 
of BRCA1 is specifi  c to cardiomyocytes, and is not dependent on 
non-myocyte factors, we cultured primary human fetal cardiomyo-
cytes derived from normal hearts aft  er elective pregnancy termina-
tion (gestational age 15  –  20 weeks) under normoxic and hypoxic 
environment  31  . We report a signifi  cant upregulation of total and 
phosphorylated BRCA1 in human fetal cardiomyocytes in response 
to  hypoxia  ( Fig.  6f ).    
 Discussion 
 Th  e   BRCA1   gene is classifi  ed as a   ‘  tumour suppressor  ’   and   ‘  care-
taker  ’   on the basis of its proposed genome integrity maintenance 
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functions  32  . Germ-line mutations in   BRCA1   predominantly  pre-
dispose carriers to breast and ovarian cancer in addition to other 
cancer syndromes  33  . BRCA1 is important for various cellular func-
tions and exerts its eff  ects on key cellular processes involved in DNA 
nucleotide excision and DSB repair, transcriptional regulation, 
ubiquitination and cell-cycle control  4,5,27,34  . Mice harbouring com-
plete ablation of BRCA1 die embryonically and display neuroepi-
thelial, proliferative and morphogenetic abnormalities  35 – 37 .  Th  e 
  BRCA1   gene is composed of 24 exons. Exon 11 is the largest exon 
and covers   ~  60  %   of the entire   BRCA1   gene 3 .  Th   e exon 11 encoded 
domain interacts and colocalizes with RAD51 at the sites of DNA 
damage to activate RAD51-mediated repair of DSBs  3,8  . Mice with 
systemic deletion of exon 11 in the   BRCA1   gene show recessive 
embryonic lethality due to impaired DNA damage-induced activa-
tion of BRCA1, compromised RAD51-dependent repair pathway 
and increased apoptosis  38,39 . 
  To understand the DNA damage repair function of BRCA1 in 
mature cardiac muscles, we utilized the   Cre-loxP   system to delete 
exon 11 of the   BRCA1   gene specifi  cally in cardiomyocytes and suc-
cessfully generated CM-BRCA1      −      /      −        mice. Although the transcrip-
tion and translation of the BRCA1    Δ 11   splice variant cannot be ruled 
out, it should be noted that if translated, it would still not encode 
the major part of the C-terminus domain and therefore would be 
non-functional with respect to the DNA damage repair properties 
of BRCA1. Baseline cardiac morphology as well as indices of car-
diac functions along with apoptosis and DNA damage were indis-
tinguishable between CM-BRCA1      −      /      −        and the WT control litter-
mates. Strikingly, whereas almost 95  %   of the CM-BRCA1      −      /      −        mice 
and   ~ 60 %   of  the  CM-BRCA1     +      /      −        mice were dead at the end of the 
study period (22 weeks), corresponding mortality in the WT mice 
was  only   ~ 20 % .  Th  ese mice died more frequently due to conges-
tive heart failure and showed dilatation of the left   ventricle. A closer 
analysis of the cardiac phenotype at 4 weeks post-MI revealed that 
CM-BRCA1      −      /      −        mice had increased infarct sizes, poor cardiac 
function, reduced contractility, dilated left   ventricles and blunted 
compensatory hypertrophy compared with WT mice. 
  Ischaemia and accompanying hypoxic stress manifested with 
increased DNA breaks are the primary triggers for the induction of 
pro-apoptotic cascades leading to apoptotic cell death  40,41 .  Given 
the central role of BRCA1 in DSB repair, we postulated that an 
ischaemic insult may result in an increased burden of DSBs and that 
under conditions of BRCA1 defi  ciency there may be accumulation of 
unresolved DSBs thereby setting the stage for cardiomyocyte apop-
tosis and cardiac dysfunction  4,5,27  . Congruent with our hypothesis, 
we observed   ~  2.5 fold greater DSBs in hearts from CM-BRCA1      −      /      −       
mice compared with those from the control littermates 48   h post-MI. 
Cardiac DSBs were resolved 72     h post-MI in WT control littermates 
but were persistently present in the hearts of CM-BRCA1      −      /      −        mice. 
Peak cardiac BRCA1 expression in WT mice occurred 72     h post-MI 
providing a clear indication that BRCA1 is required for repairing 
ischaemia-induced DSBs. Th  is fi  nding is further strengthened by 
the degree of RAD51-foci formation, another marker of DSB repair, 
which temporally correlated with MI-induced BRCA1 expression 
in WT littermates. Th  e observation that the extent of RAD51-
foci formation was reduced in the hearts of CM-BRCA1      −      /      −        mice 
post-MI suggests accumulation of unresolved DSBs, which would 
accordingly shift   the balance towards cardiomyocyte death. 
  Ischaemia-induced increased mortality and cardiac dysfunc-
tion were further associated with signifi  cantly higher numbers of 
TUNEL-positive nuclei and cleaved caspase-3 expression dem-
onstrating increased cardiomyocyte death in the hearts of CM-
BRCA1      −      /      −        mice compared with corresponding WT control lit-
termates post-MI. Systemic loss of BRCA1-associated embryonic 
lethality in mice can be partially rescued by the heterozygous 
deletion of the tumour suppressor gene   p53  18  . Intriguingly, loss of 
p53 protects the heart from rupture and associated death, whereas 
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overexpression of p53 induces cardiomyocyte apoptosis  24,42 – 44 . 
Th   erefore, we sought to determine if p53 is a modulator of cardio-
myocyte apoptosis post-MI in CM-BRCA1      −      /      −        mice. We found 
signifi  cantly higher p53 protein levels along with increased p53-
regulated pro-apoptotic downstream target Bax post-MI in the 
hearts of CM-BRCA1      −      /      −        mice.  Th  e most important factor in 
the p53-dependent survival and  /  or apoptotic signalling pathway 
is the shift   in the ratio between the pro-apoptotic Bax and pro-
survival molecule Bcl-2 (ref.   45  ), both of which are recognized as 
major regulators of cardiomyocyte apoptosis and  /  or survival deci-
sions during heart failure  25,26  . We observed that the MI-induced 
increase in cardiomyocyte apoptosis in CM-BRCA1      −      /      −        mice was 
associated with an   ~  10 fold increase in the Bax to Bcl-2 ratio, shift  -
ing the balance from a survival to an apoptotic milieu. As the sys-
temic loss of BRCA1-associated embryonic lethality in mice can be 
partially rescued by the heterozygous deletion of   p53   (refs   18,46 ), 
we investigated how deletion of one allele of   p53   would aff  ect the 
MI-induced cardiac phenotype associated with cardiomyocyte-
specifi  c loss of BRCA1. To this aim, we generated double hetero-
zygous knockout mice (CM-BRCA1      +      /      −      ;  p53     +      /      −       ). We report that 
the post-MI pheno  type associated with loss of full-length BRCA1 
could be prevented with systemic deletion of one allele of   p53 ,  such 
that the heart from the these mice show reduced apoptosis as well 
as improved cardiac function and contractility post-MI. We fur-
ther confi  rm the direct role of p53 in BRCA1 defi  ciency-associated 
post-MI cardiac phenotype by systemically deleting one allele of 
both   BRCA1   and   p53  , which mimics more of a human BRCA1-
haploinsuffi   cient condition and demonstrate that deletion of one 
allele of p53 was able to rescue the BRCA1-defi  ciency-associated 
MI-induced cardiac phenotype. 
  Chemotherapeutic agents function by directly or indirectly 
damag  ing DNA through various mechanisms  47  . Doxorubicin is a 
potent chemotherapeutic agent used for a wide variety of malignan-
cies, but the clinical utility has been limited by its dose-dependent 
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cardiotoxicity, which eventually results in refractory cardiac dys-
function  48  . Doxorubicin induces DSBs  49   and BRCA1 has been pre-
viously implicated in the repair of DSBs  4 .  Th   us the role of BRCA1 
in response to doxorubicin-induced cardiotoxicity is an impor-
tant subject for investigation. In our hands, CM-BRCA1      −      /      −        mice 
showed reduced cardiac performance, increased DSBs, reduced 
DSB repair and enhanced cardiomyocyte death in comparison to 
the WT mice following treatment with doxorubcin. 
  Of note, we provide herein evidence of clinical relevance to 
our   in vivo   observations. We report that ischaemia signifi  cantly 
upregulated BRCA1 expression in adult human atrial and ventricu-
lar tissues, and also in human fetal cardiomyocytes. Importantly, 
we also show that ischaemia signifi  cantly induced DSBs in human 
atrial tissues. BRCA1 physically interacts with RAD51 to regulate 
RAD51 nuclear transport, which is required for DSB repair  29 .  We 
propose that ischaemia induced-BRCA1 upregulation is associated 
with increased DSB repair and this is confi  rmed by greater RAD51-
foci formation in ischaemic atrial tissues. We demonstrate for the 
fi  rst time that BRCA1 protects atrial and ventricular tissues against 
DSBs by promoting DSB repair through RAD51 interaction, and 
thus loss of function or BRCA1 haplo-insuffi   ciency may lead to 
impaired DSB repair with subsequent accumulation of DNA dam-
age, apoptosis and  /  or cardiac dysfunction. 
  Taken together this study provides evidence that in the heart 
BRCA1 mediates a survival pathway that acts to block the onset 
of apoptosis resulting in cardiac dysfunction following ischaemic 
or genotoxic stress. Our data identifying BRCA1 as an essential 
and novel regulator of heart function aff  ords important transla-
tional implications. From a therapeutic standpoint, our data sug-
gest that BRCA1 may represent a novel therapeutic target to limit 
cardiac failure, a leading cause of death worldwide  50  . From an 
epidemiological standpoint, these observations provide important 
clues regarding a potential susceptibility of BRCA1 mutation car-
riers to cardiovascular disease, in addition to the well-documented 
predisposition towards cancer syndromes. Recent data suggest that 
BRCA1  /  2 mutation carriers exhibit an increase in non-neoplastic 
death particularly at older ages  51,52  . Although the causes of non-
neoplastic death in the reported population remain unknown, our 
data raise the possibility that the excess mortality may be due to 
increased rates of death from ischaemic heart disease. Finally, from 
a pharmacogenomic point of view, this data may indicate a height-
ened susceptibility of   BRCA1   mutation carriers to anthracycline-
induced cardiac failure  53  , a cornerstone of chemotherapy for breast 
and ovarian cancer.     
 Methods  
  Animal studies      .     All animal procedures were performed in accordance with 
the guidelines of the Canadian Council on Animal Care and were approved by 
the St Michael  ’  s Animal Care Committee. Studies were performed on 10  –  12 
weeks old male mice housed in a climate-controlled (temperature 22  –  24       °  C, 
humidity 40  –  60  %  ) light-regulated room with a 12     h light:12     h dark cycle. Each 
cage accommodated up to fi  ve mice and was ventilated at 60     ACH. Mice were 
maintained on irradiated   Teklad Global 18  %   Protein Rodent Diet pellets   (  Harlan 
Laboratories  ) and had   ad libitum   access to reverse osmosis water throughout 
the acclimatization and study windows. C57Bl  /  6J mice were obtained from the 
Jackson Laboratory. 
 CM-BRCA1     −      /      −        mice were generated using the   Cre-loxP   technology on a 
mixed background. Briefl  y, as shown in   Supplementary Figure S1   and   Fig. 1c  , 
mice homozygous for the exon 11 fl  oxed BRCA1 allele (BRCA1  fl    /  fl   ;  NCI,  MHCC, 
Mouse Repository; strain  #   01XC8, strain name: Brca1  tm2Cxd ) 3   were crossed with 
hemizygous mice expressing   Cre-recombinase   under the control of the   α  -myosin 
heavy chain   ( α MHC- Cre    tg /  )  promoter 19  . Mice of the   α MHC- Cre    tg /  ;BRCA1 fl    /     +      
combination were denoted as cardiomyocyte-specifi  c BRCA1 heterozygous 
(CM-BRCA1      +      /      −       ) and those with the   α MHC- Cre    tg /  ;BRCA1 fl    /  fl     combination  as 
cardiomyocyte-specifi  c BRCA1 homozygous (CM-BRCA1      −      /      −      )  knockouts.  Mice 
were genotyped using routine PCR with the following sets of primers: 
 004:5 ′ -CTGGGTAGTTTGTAAGCATGC-3 ′  
 005:5 ′ -CAATAAACTGCTGGTTCTAGG-3 ′  
 006:5 ′ -CTGCGAGCAGTCTTCAGAAAG-3 ′  
  α MHC- Cre   transgene 
 Forward-5 ′ -ATGACAGACAGATCCCTCCTATCTCC-3 ′  
 Reverse-5 ′ -CTCATCACTCGTTGCATCGAC-3 ′  
  To generate CM-BRCA1      −      /      −        mice with a p53      +      /      −        background,   α MHC- Cre    tg /  ;
BRCA1  fl    /  fl     mice were crossed with   p53      +      /      −        mice   ( Jackson  Laboratory ;  stock #  
002101, strain name: B6.129S2-Trp53  tm1Tyj / J ).  Th   is resulted in mice with one allele 
of   BRCA1   in their cardiomyocytes while presenting with systemic loss of one allele 
of   p53   (  α MHC   Cre    tg /  ;BRCA1 fl    /     +     ;p53     +      /      −        denoted as CM-BRCA1      +      /      −      ;p53     +      /      −      ). 
B6.129S2-Trp53  tm1Tyj / J   mice were genotyped as suggested by   Jackson Labora-
tory  . We also utilized BRCA1      +      /   Δ 11   mice with a p53      +      /      −        background by crossings 
BRCA1      +      /   Δ 11   mice with p53      +      /      −        mice 54 .   
  Experimental MI   .    Mice  (10 – 12  weeks)  underwent  coronary  artery  ligation  to 
induce MI as previously published  55 – 58  . Analgesia was provided with 0.1     mg     kg      −     1  
Buprenex before deep anaesthesia was induced with isofl  urane in an anaesthetic 
chamber. Th   e surgical plane was maintained under 1  –  1.5  %   isofl  urane. Mice were 
intubated with a 20-G intravenous cannula that was subsequently connected to 
a   mouse  ventilator   ( Minivent ,   Harvard  Apparatus )  via  a  Y-shaped  connector. 
Mechanical ventilation was accomplished with 100  %   oxygen at a tidal volume 
of  200    μ  l and a respiratory rate of 133     cycles per min. Th   e site above the left   4th 
intercostal space was disinfected before an incision (  ~  1     cm in length) perpen-
dicular to the sternum was made. Th   e ribs were retracted with 4-0 silk suture 
and the pericardium pulled apart gently to render a clear view of the heart and 
its vascular structures. Th  e  left   coronary artery was visualized as a pulsating 
bright red spike running in the midst of the heart wall from underneath of the 
left   atrium towards the apex. Procedural consistency was maintained by ligating 
the left   coronary artery, with a 7-0 silk suture and an atraumatic needle,   ~  1     mm 
below the tip of the left   auricle. Occlusion was confi  rmed by the immediate pallor 
of the anterior wall of the LV, regional hypokinesia and enlargement of the LV. 
Th   e pericardium was returned as close as possible to its pre-opening state. Th  e 
chest cavity was closed and the muscles and skin closed layer by layer with 4-0 
silk sutures. Following extubation, mice were allowed to recover in an incubator 
set at 30       °  C until they were fully ambulatory. Th   e duration of the entire procedure 
was   ~ 15 – 20   min.   
  Two-dimensional echocardiography   .    Two-dimensional  echocardiography  ( HDI 
5000cv  ,   Philips Ultrasound  ) was performed by a blinded investigator on sedated 
(1 – 1.5 %   isofl  urane) mice using a high-frequency linear transducer (CL 15-7). 
Short-axis M-mode and two-dimensional images and loops of the LV at the mid-
papillary muscle level were digitally acquired, stored and analyzed off  -line. End 
diastolic posterior wall thickness and LV end diastolic diameter (LVEDD) were de-
termined from frames taken at maximum cavity size. Dimensions of LV systolic di-
ameter (LVESD) were recorded during maximum anterior motion of the posterior 
wall. Final values represent the average measurement of three consecutive cardiac 
cycles. Fractional shortening was defi   ned  as  ((LVEDD    −    LVESD) / LVEDD)  and  LV 
ejection fraction was calculated from ((LVEDD  3     −    LVESD 3 ) / LVEDD 3 ) × 100.   
  Haemodynamic measurements   .    Closed-chest  haemodynamic  assessments 
were  performed  on  anesthetized  (1 – 1.5 %   isofl  urane) mice. Mice were intubated 
and mechanically ventilated (133 cycles per min) with 100  %   oxygen. Th   e LV was 
accessed  with  a  1.4F  miniaturized  impedance /  micromanometer  catheter   ( Millar 
Instruments  ) through the right carotid artery. Th   e inferior vena cava was isolated 
immediately below the diaphragm for transient occlusion by applying gentle pres-
sure with a cotton swab. LV pressure  –  volume relationships, acquired at a sampling 
rate of 1     kHz during steady state and transient occlusion of the inferior vena cava, 
were stored for off  -line analysis. Calibration of volume signals from the conduct-
ance catheter was achieved by administration of 10  %   saline into the right jugular 
vein followed by calculation of the slope. External cuvette calibrations were also 
routinely performed to convert relative volume units to absolute volume measure-
ments (in   μ  l). Following study completion, the hearts were harvested and weighed 
before undergoing gross anatomical examinations.     
  Determination of area at risk   .    Evans  blue  (1.0 % ;  Sigma)  was  injected  retrograde 
through the abdominal aorta to delineate the non-ischaemic tissue before the heart 
was excised, washed with PBS and sliced into four transverse sections. Slices were 
stained for 20     min at 37       °  C with 1.0     ml of 1.5  %     2,3,5-triphenyltetrazolium chloride   
(  Sigma  ) to determine the infarct area. Sections were photographed and the area at 
risk quantifi  ed with the aid of the   NIH ImageJ soft   ware .   
  Histology      .     Histological studies were performed on hearts that were fi  xed   in situ  
and stored in 3.7  %   paraformaldehyde or on hearts that were frozen in OCT and 
cryosectioned  (5    μ  m). For gross histological examinations, sections (5  –  8       μ m) 
were stained with haematoxylin and eosin. Infarct size was calculated as the ratio 
of total infarct to total endocardial circumference times 100. TUNEL staining 
was performed on deparaffi   nized sections either by routine DAB staining or with 
the   Promega DeadEnd Fluorometric TUNEL kit   and visualized by   fl  uorescent 
confocal  microscopy   ( Leica ).  Th   e percentage of TUNEL-positive nuclei (per 
1000) in each remote myocardial section was quantifi  ed and averaged from 5  –  7 
randomly selected high-power (  ×  400) fi  elds. Other sections were examined via 
routine immunohistochemical methods using antibodies directed against   BRCA1   ARTICLE
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(1:400;   Santa Cruz  ),     γ H2A.X   (1:100;   Millipore ),   RAD51   (1:100;   Millipore )  and   total 
caspase-3   (1:200;   Cell  Signaling ).   
  RNA measurements      .     Total whole heart RNA was extracted with   trizol reagent   
(  Invitrogen  ) and reverse transcribed with the   Quantitect Reverse Transcription Kit   
(  Qiagen  ). Real-time reactions were carried out with a SYBR Green master mix on 
the   PRISM 7900HT system   (both   Applied Biosystems  ) using the following primers: 
 BRCA1 
 Forward-5 ′ -ATCTGCCGTCCAAATTCAAG-3 ′  
 Reverse-5 ′ -TTCCAAACAGATCGGACACTC-3 ′  
  Brain natriuretic peptide 
 Forward-5 ′ -ACAAGATAGACCGGATCGGA-3 ′  
 Reverse-5 ′ -ACCCAGGCAGAGTCAGAAAC-3 ′  
 GAPDH 
 Forward-5 ′ -TGGATGCAGGGATGATGTTCT-3 ′  
 Reverse-5 ′ -TGCACCACCAACTGCTTAGCC-3 ′    
  Western blotting      .     Total protein, extracted with ice-cold   RIPA buff   er   ( Sigma ) 
containing a   protease inhibitor cocktail   (  Roche  ), was quantifi  ed with the   Bio-Rad 
Protein Assay Reagent  . Protein samples (50       μ  g) were separated by SDS-polyacryla-
mide gel electrophoresis, transferred to nitrocellulose membranes and probed with 
 antibodies   from   Genway   ( BRCA1   (6B4),  1:750),   Cell  Signalling   ( p53 ;   Bax ;   cleaved 
caspase-3  ; all at a 1:1000 dilution) or   Millipore   (  Bcl-2  , 1:1000;     γ H2A.X ,  1:1000; 
 GADPH ,  1:4000;    α  -actin  , 1:10,000). Following incubation with the appropriate 
  horseradish peroxidase-associated secondary antibodies   (  Santa Cruz  ), signals were 
visualized with an   enhanced chemiluminescence detection system   (  Amersham 
Bioscience  ) and quantifi   ed  by  densitometry.   
  Human samples      .     Approval was received from the Research Ethics Boards of 
St Michael  ’  s Hospital and the Hospital for Sick Children. Participation was volun-
tary and informed consent was obtained in all cases. Atrial samples were obtained 
from patients undergoing cardiac surgery with CP and CPB for coronary artery 
bypass graft   surgery  30  . Pre-CP  /  CPB right atrial appendages were isolated using a 
double purse-string suture method during the placement of the venous cannula. 
Post-CP  /  CPB samples were collected aft  er weaning from bypass and a brief period 
of reperfusion (5  –  15     min). Samples were fl  ash frozen and processed for western 
blot and immunohistochemistry studies. Ventricular sections from sites distal to 
major coronary obstruction (patients undergoing coronary artery bypass graft   sur-
gery; ischaemic) and from sites with no clinical symptoms of ischaemia (patients 
undergoing valve replacement; non-ischaemic) were snap frozen and processed 
for immunohistochemical work. We ensured that the samples obtained for the is-
chaemic group were from areas that were chronically ischaemic yet viable, and not 
infarcted. Th   ey were from areas of the myocardium with planned revascularization. 
Semi-quantitative analysis to determine the extent of DAB staining in each section 
was performed with the   ImageJ soft   ware   ( http://rsb.info.nih.gov/ij/ ).  Measurements 
were averaged to obtain a single value for each patient and in turn data from the 
patients in each group were averaged to obtain a single value for statistical analysis. 
Primary human fi  broblast-conditioned media (HFCM) cultures were prepared 
from structurally normal hearts aft  er elective pregnancy termination (gestational 
age, 15  –  20 weeks). Following enzymatic digestion with a 0.05  %     trypsin-collagenase 
solution   (  Life Technologies  ) at 37       °  C, dissociated cells were concentrated from the 
supernatant and plated in 10  %   fetal bovine serum-supplemented Dulbecco  ’  s-modi-
fi  ed Eagle  ’  s medium to allow for identifi  cation and removal of non-cardiomyocytes. 
Th   is method yields cultures containing   ~  80  %     β  -myosin heavy chain-positive car-
diac myocytes  31  . To simulate ischaemia, PBS-washed HFCM cultures were trans-
ferred to a pH 6.5 simulated solution containing 100     ml of deionized water, 0.8     g 
NaCl, 0.119     ml of N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid, 0.164     g 
2-deoxyglucose, 0.89     ml KCl, 0.472     ml CaCl  2 ,  0.238   ml  of  MgCl 2   and  0.135   ml  of 
  DL  -lactic acid saturated in 100  %   N  2  for 1     h, followed by addition of 0.1     g of bovine 
serum albumin. Aft  er incubation for 24     h under 100  %   N  2  at 37       °  C, HFCM cultures 
were processed for western blot analysis. Control HFCM cultures were maintained 
in fetal bovine serum-supplemented Dulbecco  ’  s-modifi  ed Eagle  ’  s medium at 37       °  C 
in a standard CO  2   i n c u b a t o r.                       
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